FKC389

FKC389 is an investigational universal (allogeneic) chimeric antigen receptor T-cell (CAR-T) therapy being developed by Fosun Kairos, the innovation arm of Fosun Kite. Unlike traditional autologous CAR-T therapies that require manufacturing from a patient's own cells, FKC389 is designed as an 'off-the-shelf' product derived from healthy donor cells. This approach aims to reduce treatment wait times and manufacturing costs while increasing accessibility. The therapy is currently in preclinical development for the treatment of various hematologic malignancies and autoimmune diseases. While the specific molecular target has not been publicly disclosed in pipeline listings, the program represents Fosun Kairos's expansion into next-generation allogeneic cell therapy platforms.